Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/12769/Gencer-Salih-2024.pdf.jpg?sequence=4&isAllowed=y)
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttps://creativecommons.org/licenses/by-nc-nd/4.0/Tarih
2024Yazar
Wofford, WyattKim, Jisun
Kim, Dosung
Janneh, Alhaji H.
Lee, Han Gyul
Atılgan, Cansu
Oleinik, Natalia
Kassir, Mohamed Faisal
Saatçi, Özge
Chakraborty, Paramita
Tokat, Ünal Metin
Gencer, Salih
Howley, Breege
Howe, Philip
Mehrotra, Shikhar
Şahin, Özgür
Öğretmen, Besim
Üst veri
Tüm öğe kaydını gösterKünye
Wofford, W., Kim, J., Kim, D., Janneh, A. H., Lee, H. G., Atılgan, C. ... Öğretmen, B. (2024). Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response. Cell Reports, 43(8). http://dx.doi.org/10.1016/j.celrep.2024.114532Özet
Programmed death ligand 1, PD-L1 (CD274), facilitates immune evasion and exerts pro-survival functions in cancer cells. Here, we report a mechanism whereby internalization of PD-L1 in response to alterations of bioactive lipid/ceramide metabolism by ceramide synthase 4 (CerS4) induces sonic hedgehog (Shh) and transforming growth factor β receptor signaling to enhance tumor metastasis in triple-negative breast cancers (TNBCs), exhibiting immunotherapy resistance. Mechanistically, data showed that internalized PD-L1 interacts with an RNA-binding protein, caprin-1, to stabilize Shh/TGFBR1/Wnt mRNAs to induce β-catenin signaling and TNBC growth/metastasis, consistent with increased infiltration of FoxP3+ regulatory T cells and resistance to immunotherapy. While mammary tumors developed in MMTV-PyMT/CerS4−/− were highly metastatic, targeting the Shh/PD-L1 axis using sonidegib and anti-PD-L1 antibody vastly decreased tumor growth and metastasis, consistent with the inhibition of PD-L1 internalization and Shh/Wnt signaling, restoring anti-tumor immune response. These data, validated in clinical samples and databases, provide a mechanism-based therapeutic strategy to improve immunotherapy responses in metastatic TNBCs.
Scopus Q Kategorisi
Q1Kaynak
Cell ReportsCilt
43Sayı
8Koleksiyonlar
- Makale Koleksiyonu [3790]
- Makale Koleksiyonu [188]
- PubMed İndeksli Yayınlar Koleksiyonu [4251]
- Scopus İndeksli Yayınlar Koleksiyonu [6601]